Skip to main content
Erschienen in: International Journal of Clinical Oncology 9/2020

11.07.2020 | COVID-19 | Original Article Zur Zeit gratis

Evaluation of COVID 19 infection in 279 cancer patients treated during a 90-day period in 2020 pandemic

verfasst von: Mozaffar Aznab

Erschienen in: International Journal of Clinical Oncology | Ausgabe 9/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

The aim of this study was investigation of COVID-19 disease and its outcome in cancer patients who needed treatment, in a 90-day period.

Methods

Cancer patient who required treatment, were evaluated for potential COVID-19 infection in a 90-day period, starting from beginning of this epidemic in Iran, January, to April 19, 2020. For treatment of solid tumor patients, if they did not have symptoms related to COVID-19, just chest X-ray was requested. If they showed COVID-19 related symptoms, high resolution CT scan of lungs was requested. For hematology cancer patients, PCR test for COVID-19 infection was requested as well. Protection measures were considered for personnel of oncology wards.

Results

279 Patients were followed up in this 90-day period. No COVID-19 infection was observed in 92 cases of breast cancer, 14 cases of gastric cancer and 12 cases of pancreaticobiliary cancer. However, in 72 cases of colon cancer, 11 cases of lung cancer, 5 cases brain tumors and 12 cases ovarian cancer; 4 cases of COVID-19 were observed. In the hematology cancers group, which included 14 cases of Hodgkin’s disease, 23 cases of lymphoproliferative disorder, 12 cases of acute leukemia and 12 cases of multiple myeloma; 3 cases of COVID-19 were observed.

Conclusion

Patients with cancer who need treatment can be treated by taking some measures. These measures include observing individual and collective protection principles in patients and health-care personnel, increasing patients’ awareness particularly about self-care behavior, performing a COVID-19 test, and taking a chest X-ray, before the treatment starts
Literatur
1.
Zurück zum Zitat Zhu N, Zhang D, Wang W et al (2020) A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382:727–733CrossRef Zhu N, Zhang D, Wang W et al (2020) A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382:727–733CrossRef
2.
Zurück zum Zitat Wu F, Zhao S, Yu B et al (2020) A new coronavirus associated with human respiratory disease in China. Nature 579:265–269CrossRef Wu F, Zhao S, Yu B et al (2020) A new coronavirus associated with human respiratory disease in China. Nature 579:265–269CrossRef
4.
Zurück zum Zitat Li Q, Guan X, Wu P et al (2020) Early transmission dynamics in Wuhan, China, of novel Coronavirus-infected pneumonia. N Engl J Med 382:1199–1207CrossRef Li Q, Guan X, Wu P et al (2020) Early transmission dynamics in Wuhan, China, of novel Coronavirus-infected pneumonia. N Engl J Med 382:1199–1207CrossRef
5.
Zurück zum Zitat Backer JA, Klinkenberg D, Wallinga J (2020) Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20–28 January 2020. Euro Surveill 25(5):2000062CrossRef Backer JA, Klinkenberg D, Wallinga J (2020) Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20–28 January 2020. Euro Surveill 25(5):2000062CrossRef
6.
Zurück zum Zitat To KK, Tsang OT, Chik-Yan Yip C et al (2020) Consistent detection of 2019 novel coronavirus in saliva. Clin Infect Dis To KK, Tsang OT, Chik-Yan Yip C et al (2020) Consistent detection of 2019 novel coronavirus in saliva. Clin Infect Dis
7.
Zurück zum Zitat Centers for Disease Control and Prevention (2020) People who are at higher risk for severe illness. Coronavirus Disease 2019 (COVID-19) Centers for Disease Control and Prevention (2020) People who are at higher risk for severe illness. Coronavirus Disease 2019 (COVID-19)
9.
Zurück zum Zitat Matti A, Alfredo A, Paolo A et al. (2020) Cancer patient management during COVID-19 pandemic. ESMO Recommendations Matti A, Alfredo A, Paolo A et al. (2020) Cancer patient management during COVID-19 pandemic. ESMO Recommendations
11.
Zurück zum Zitat Aznab M, Rezaei M (2017) Induction, consolidation, and maintenance therapies with arsenic as a single agent for acute promyelocytic leukaemia in a 11-year follow-up. Hematol Oncol 35:113–117CrossRef Aznab M, Rezaei M (2017) Induction, consolidation, and maintenance therapies with arsenic as a single agent for acute promyelocytic leukaemia in a 11-year follow-up. Hematol Oncol 35:113–117CrossRef
12.
Zurück zum Zitat Aznab M, Rezaei M, Navabi J et al (2017) Evaluation of low-dose thalidomide as induction and maintenance therapy in patients with multiple myeloma not eligible for stem cell transplantation. APCO 13:e138–e143 Aznab M, Rezaei M, Navabi J et al (2017) Evaluation of low-dose thalidomide as induction and maintenance therapy in patients with multiple myeloma not eligible for stem cell transplantation. APCO 13:e138–e143
Metadaten
Titel
Evaluation of COVID 19 infection in 279 cancer patients treated during a 90-day period in 2020 pandemic
verfasst von
Mozaffar Aznab
Publikationsdatum
11.07.2020
Verlag
Springer Singapore
Schlagwort
COVID-19
Erschienen in
International Journal of Clinical Oncology / Ausgabe 9/2020
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-020-01734-6

Weitere Artikel der Ausgabe 9/2020

International Journal of Clinical Oncology 9/2020 Zur Ausgabe

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.